Alimera Sciences, Inc. (ALIM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alimera Sciences, Inc. (ALIM) trades at $5.54 with AI Score 60/100 (Grade B+). Alimera Sciences, Inc. is a pharmaceutical company focused on the development and commercialization of ophthalmic pharmaceuticals. Market cap: $301.29M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for ALIM: ALIM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALIM against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ALIM: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bearish.
Alimera Sciences, Inc. (ALIM) Healthcare & Pipeline Overview
Alimera Sciences, Inc. specializes in ophthalmic pharmaceuticals, primarily ILUVIEN for diabetic macular edema (DME) and uveitis. With a 75.7% gross margin, the company operates in a competitive market, focusing on direct sales and distribution to physician offices, pharmacies, and hospitals internationally.
What Is the Investment Thesis for ALIM?
Alimera Sciences presents a focused investment opportunity within the ophthalmic pharmaceutical space. The company's reliance on a single key product, ILUVIEN, for treating DME and uveitis creates both potential and risk. A 75.7% gross margin indicates strong pricing power, but a negative profit margin of -24.9% highlights the need for improved operational efficiency and cost management. Growth catalysts include further penetration of existing markets and potential expansion into new geographic regions. The collaboration with EyePoint Pharmaceuticals for novel drug delivery technologies could also unlock future value. However, investors should be aware of the risks associated with reliance on a single product, competition from alternative treatments, and the potential for regulatory or reimbursement challenges. With a market capitalization of $0.30 billion and a negative P/E ratio of -7.03, Alimera is a high-risk, high-reward investment that requires careful monitoring of sales growth, profitability trends, and pipeline development.
Based on FMP financials and quantitative analysis
ALIM Key Highlights
- ILUVIEN is Alimera's primary product, an intravitreal implant for treating diabetic macular edema (DME) and preventing relapse in recurrent non-infectious uveitis.
- Gross margin of 75.7% indicates strong pricing power in the ophthalmic pharmaceutical market.
- Negative profit margin of -24.9% suggests challenges in managing operating expenses and achieving profitability.
- Market capitalization of $0.30 billion positions Alimera as a small-cap company with potential for growth but also higher risk.
- Collaboration agreement with EyePoint Pharmaceuticals for developing novel drug delivery technologies represents a potential growth catalyst.
Who Are ALIM's Competitors?
ALIM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| CYTH Cyclo Therapeutics, Inc. | $0.72 | +0.00% | $23.59M | 50 |
| DERM Journey Medical Corporation | $6.26 | -0.14% | $172.31M | 49 |
| ALVO Alvotech | $4.17 | -1.18% | 2B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.61 | +1.67% | $8.03M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALIM's Key Strengths?
- Proprietary intravitreal implant technology (ILUVIEN).
- High gross margin (75.7%).
- Focus on a specific niche within ophthalmology (DME and uveitis).
- Established distribution network.
What Are ALIM's Weaknesses?
- Reliance on a single product (ILUVIEN).
- Negative profit margin (-24.9%).
- Limited product pipeline.
- Small market capitalization ($0.30 billion).
What Could Drive ALIM Stock Higher?
- Potential regulatory approvals for ILUVIEN in new geographic markets.
- Continued expansion of the ILUVIEN sales force and marketing efforts.
- Progress in the collaboration with EyePoint Pharmaceuticals for new drug delivery technologies.
- Publication of clinical trial data supporting the efficacy and safety of ILUVIEN in new indications.
What Are the Key Risks for ALIM?
- Competition from new and existing treatments for DME and uveitis.
- Regulatory challenges and reimbursement pressures affecting ILUVIEN sales.
- Patent expiration and potential generic competition for ILUVIEN.
- Dependence on a single product (ILUVIEN) for the majority of revenue.
What Are the Growth Opportunities for ALIM?
- Geographic Expansion: Expanding into new international markets represents a significant growth opportunity for Alimera. The prevalence of DME and uveitis is increasing globally, creating demand for effective treatments like ILUVIEN. Successfully navigating regulatory approvals and establishing distribution partnerships in key markets such as China and India could drive substantial revenue growth over the next 3-5 years. This expansion would require significant investment in marketing and sales infrastructure, but the potential return could be substantial.
- Pipeline Expansion: Developing and commercializing new ophthalmic pharmaceuticals beyond ILUVIEN is crucial for Alimera's long-term growth. The collaboration with EyePoint Pharmaceuticals offers a pathway to expand the product pipeline with novel drug delivery technologies. Successfully developing and launching new products targeting other eye diseases could diversify Alimera's revenue streams and reduce its reliance on a single product. This pipeline expansion could take 3-7 years depending on clinical trial timelines and regulatory approvals.
- Increased Market Penetration: Increasing the market share of ILUVIEN within its existing indications (DME and uveitis) represents a near-term growth opportunity. This can be achieved through targeted marketing campaigns, physician education programs, and improved patient access. By demonstrating the clinical benefits and cost-effectiveness of ILUVIEN compared to alternative treatments, Alimera can drive increased adoption and sales growth. This strategy could yield results within the next 1-2 years.
- Strategic Partnerships and Acquisitions: Pursuing strategic partnerships or acquisitions could accelerate Alimera's growth and expand its capabilities. Partnering with other pharmaceutical companies or research institutions could provide access to new technologies, products, or markets. Acquiring complementary businesses could broaden Alimera's product portfolio and customer base. These opportunities could materialize within the next 2-4 years, depending on market conditions and available capital.
- New Indications for ILUVIEN: Exploring new potential indications for ILUVIEN beyond DME and uveitis could unlock additional growth opportunities. Clinical trials to evaluate the efficacy and safety of ILUVIEN in treating other eye diseases could expand its market potential and extend its product lifecycle. This strategy carries significant risk due to the uncertainty of clinical trial outcomes, but the potential reward could be substantial if successful. This process could take 4-6 years.
What Opportunities Does ALIM Have?
- Geographic expansion into new markets.
- Development of new indications for ILUVIEN.
- Expansion of product pipeline through collaborations or acquisitions.
- Increased market penetration in existing markets.
What Threats Does ALIM Face?
- Competition from alternative treatments for DME and uveitis.
- Regulatory challenges and reimbursement pressures.
- Patent expiration and potential generic competition.
- Economic downturn affecting healthcare spending.
What Are ALIM's Competitive Advantages?
- Proprietary drug formulation of ILUVIEN.
- Intravitreal implant technology for targeted drug delivery.
- Established relationships with physician offices, pharmacies, and hospitals.
- Collaboration agreement with EyePoint Pharmaceuticals for innovative drug delivery systems.
What Does ALIM Do?
Alimera Sciences, Inc., founded in 2003 and headquartered in Alpharetta, Georgia, is a pharmaceutical company dedicated to the development and commercialization of ophthalmic pharmaceuticals. The company's flagship product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a debilitating condition affecting individuals with diabetes that can lead to significant vision loss and blindness. ILUVIEN is also used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. Alimera markets and sells ILUVIEN through a combination of direct sales and distribution partnerships, targeting physician offices, pharmacies, and hospitals both in the United States and internationally. This dual approach allows the company to maintain control over key markets while leveraging established distribution networks to expand its reach. The company also has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera operates in a competitive landscape within the specialty pharmaceutical sector, facing competition from larger, more established companies as well as smaller, innovative firms. The company's focus on a specific niche within ophthalmology, coupled with its proprietary drug delivery technology, differentiates it from some of its competitors. However, Alimera must continue to innovate and expand its product pipeline to maintain its competitive edge and drive future growth.
What Products and Services Does ALIM Offer?
- Develops and commercializes ophthalmic pharmaceuticals.
- Offers ILUVIEN, an intravitreal implant for treating diabetic macular edema (DME).
- Provides ILUVIEN to prevent relapse in recurrent non-infectious uveitis.
- Sells products to physician offices, pharmacies, and hospitals.
- Utilizes direct sales and distributors to reach customers.
- Collaborates with EyePoint Pharmaceuticals for drug delivery technology.
How Does ALIM Make Money?
- Develops and manufactures ILUVIEN, an intravitreal implant.
- Sells ILUVIEN directly to physician offices, pharmacies, and hospitals.
- Utilizes distributors to expand market reach internationally.
- Generates revenue through product sales.
What Industry Does ALIM Operate In?
Alimera Sciences operates within the specialty pharmaceutical industry, specifically targeting the ophthalmic market. This market is characterized by increasing prevalence of eye diseases such as diabetic macular edema (DME) and uveitis, driven by aging populations and rising rates of diabetes. The competitive landscape includes both large pharmaceutical companies with broad product portfolios and smaller, specialized firms focused on niche markets. Alimera's success depends on its ability to effectively commercialize ILUVIEN, expand its product pipeline, and navigate the complex regulatory and reimbursement environment.
Who Are ALIM's Key Customers?
- Physician offices specializing in ophthalmology.
- Pharmacies that dispense ophthalmic medications.
- Hospitals with ophthalmology departments.
- Patients suffering from diabetic macular edema (DME).
- Patients with recurrent non-infectious uveitis.
ALIM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Alimera's future, indicating that leadership believes in the company's value.
- Community sentiment has shifted positively with discussions around potential new product launches gaining traction.
- The company has been making strides in expanding its treatment options, which could enhance its market position.
- Positive feedback from recent clinical trials has generated excitement within the investor community, fostering a bullish outlook.
Bear Case
- Concerns over the company's cash flow management have surfaced, leading to skepticism about its financial sustainability.
- Recent social sentiment indicates a cautious approach among investors, with many expressing doubts about the company's long-term strategy.
- Market perception remains wary due to competitive pressures in the ophthalmic space, which could hinder growth.
- Negative commentary around regulatory hurdles has emerged, raising fears about potential delays in product approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
ALIM Latest News
-
Earnings Scheduled For August 10, 2023
benzinga · Aug 10, 2023
-
Earnings Scheduled For May 9, 2022
benzinga · May 9, 2022
-
New 52-Week Lows for Tuesday Morning
· Jul 30, 2019
ALIM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALIM.
Price Targets
Wall Street price target analysis for ALIM.
ALIM MoonshotScore
What does this score mean?
The MoonshotScore rates ALIM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Richard S. Eiswirth Jr.
Chief Executive Officer
Richard S. Eiswirth Jr. has extensive experience in the pharmaceutical and healthcare industries. His career spans various leadership roles in sales, marketing, and general management. Prior to joining Alimera Sciences, he held executive positions at several pharmaceutical companies, where he was responsible for driving revenue growth, launching new products, and expanding market share. He has a strong track record of building and leading high-performing teams and developing successful commercial strategies.
Track Record: Under Richard S. Eiswirth Jr.'s leadership, Alimera Sciences has focused on expanding the market reach of ILUVIEN and improving operational efficiency. Key achievements include securing strategic partnerships, navigating regulatory hurdles, and driving revenue growth in key markets. His focus on commercial execution and strategic planning has been instrumental in positioning Alimera for future success.
What Investors Ask About Alimera Sciences, Inc. (ALIM) — Healthcare
What does Alimera Sciences, Inc. do?
Alimera Sciences, Inc. is a pharmaceutical company specializing in the development and commercialization of ophthalmic pharmaceuticals. Its primary product, ILUVIEN, is an intravitreal implant used to treat diabetic macular edema (DME) and prevent relapse in recurrent non-infectious uveitis. The company focuses on direct sales and distribution to physician offices, pharmacies, and hospitals, primarily targeting patients suffering from these specific eye conditions. Alimera operates in a competitive market, striving to expand its market share and develop new products through strategic collaborations.
What do analysts say about ALIM stock?
Analyst coverage of Alimera Sciences, Inc. (ALIM) is limited, but generally focuses on the potential of ILUVIEN and the company's ability to achieve profitability. Key valuation metrics include revenue growth, gross margin, and operating expenses. Analysts monitor the company's progress in expanding market share, navigating regulatory hurdles, and developing new products. The consensus view is cautiously optimistic, recognizing the risks associated with a single-product company but also acknowledging the potential for growth in the ophthalmic market. No buy or sell recommendations are made here.
What are the main risks for ALIM?
Alimera Sciences faces several key risks, including its reliance on a single product, ILUVIEN, for the majority of its revenue. Competition from alternative treatments for DME and uveitis poses a significant threat. Regulatory challenges and reimbursement pressures can impact ILUVIEN sales. Patent expiration and potential generic competition could erode market share. Additionally, the company's negative profit margin highlights the need for improved operational efficiency and cost management. Successfully mitigating these risks is crucial for Alimera's long-term success.
How does Alimera Sciences, Inc. navigate regulatory approval processes?
Alimera Sciences, Inc. navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its products, primarily ILUVIEN. The company works closely with regulatory agencies like the FDA in the United States and EMA in Europe to ensure compliance with all applicable regulations and guidelines. Alimera's regulatory strategy involves submitting comprehensive data packages, addressing agency queries promptly, and maintaining open communication throughout the approval process. Successfully navigating these regulatory hurdles is crucial for expanding the market reach of ILUVIEN and launching new products.
How does Alimera Sciences, Inc. manage patent expiration risks?
Alimera Sciences, Inc. manages patent expiration risks by actively monitoring its patent portfolio and pursuing strategies to extend the lifecycle of its products, particularly ILUVIEN. This includes seeking patent protection for new formulations, delivery methods, and indications. The company also explores strategic partnerships and collaborations to develop new products and technologies that can diversify its revenue streams and reduce its reliance on ILUVIEN. Proactive patent management and pipeline development are essential for mitigating the impact of patent expirations and maintaining a competitive advantage.
What are the key factors to evaluate for ALIM?
Alimera Sciences, Inc. (ALIM) holds an AI score of 60/100 (moderate). Not financial advice.
How frequently does ALIM data refresh on this page?
ALIM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALIM's recent stock price performance?
Alimera Sciences, Inc. (ALIM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary intravitreal implant technology (ILUVIEN). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage available. Financial data based on publicly available information.